Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors  Jules L. Derks, MD, Robert Jan.

Published byClement Scott Modified over 5 years ago

Similar presentations

Presentation on theme: "A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors  Jules L. Derks, MD, Robert Jan."— Presentation transcript:

1 A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors  Jules L. Derks, MD, Robert Jan van Suylen, MD, PhD, Erik Thunnissen, MD, PhD, Michael A. den Bakker, MD, PhD, Egbert F. Smit, MD, PhD, Harry J.M. Groen, MD, PhD, Ernst J.M. Speel, MS, PhD, Anne-Marie C. Dingemans, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Flowchart presenting an overview of selection of conclusions from pathology reports after manual screening of 7989 pathology conclusion texts. After application of exclusion criteria, 3052 unique patient conclusions were eligible for diagnostic nomenclature analysis. PALGA, Dutch Pathology Registry; SCLC, small cell lung cancer; NSCC, non–small cell cancer; LCC, large cell carcinoma; DIPNEC, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia; NEC, neuroendocrine carcinoma; NOS, not otherwise specified; DD, differential diagnosis; Ca, carcinoma; Diff, differentiation. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 An overview of diagnoses with non-WHO nomenclature versus diagnoses made according to the WHO nomenclature and separated for the following clusters: carcinoid, high-grade neuroendocrine carcinoma and LCC/NSCC, and carcinoma with neuroendocrine features or differentiation. The exact number of all retrieved diagnoses based on non-WHO nomenclature can be found in Supplementary Table 1. WHO, World Health Organization; NOS, not otherwise specified; Diff, differentiation; NSCC, non–small cell carcinoma; LCC, large cell carcinoma. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 (A) Overview of all diagnoses clustered as carcinoid and separated for type of sampling method. (B) Overview of all diagnoses clustered as high-grade neuroendocrine carcinomas and separated for type of sampling method. (C) Overview of sampling methods used to diagnose all typical/atypical and carcinoid NOS diagnoses from 2003 to (D) Overview of sampling methods used to diagnose LCNEC from 2003 to *The diagnosis of carcinoid NOS presented here is a combination of the diagnoses “carcinoid, no atypical features; carcinoid, unsure whether typical or atypical; and carcinoid NOS” from Supplementary Table 1. †Here the nonsurgically obtained biopsy specimen is a referral for the cluster of transbronchial and endobronchial biopsy specimens and needle biopsy specimens. WHO, World Health Organization; NOS, not otherwise specified; SCLC, small cell lung cancer; LCNEC large cell neuroendocrine carcinoma; NSCLC, non–small cell lung cancer; LCNEM, large cell carcinoma with neuroendocrine morphological features but not neuroendocrine immunohistochemistrical staining results. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors  Jules L. Derks, MD, Robert Jan."

Similar presentations

Discriminant Model for Cytologic Distinction of Large Cell Neuroendocrine Carcinoma from Small Cell Carcinoma of the Lung  Rira Hoshi, CT, Noriyuki Furuta,

Discriminant Model for Cytologic Distinction of Large Cell Neuroendocrine Carcinoma from Small Cell Carcinoma of the Lung  Rira Hoshi, CT, Noriyuki Furuta,
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.
Unilateral Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia and Multiple Carcinoids Treated with Surgical Resection  Sheeba Irshad, Emma McLean,

Unilateral Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia and Multiple Carcinoids Treated with Surgical Resection  Sheeba Irshad, Emma McLean,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung  Adi F. Gazdar, MD, Trisha K. Savage, MS, Jane.

The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung  Adi F. Gazdar, MD, Trisha K. Savage, MS, Jane.
Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease  Andrew E. Hendifar,

Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease  Andrew E. Hendifar,
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

Similar presentations

Ads by Google